New MS drug trial uses Super-Powered MRI to see inside the brain
NCT ID NCT07222956
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called remibrutinib in 20 people with relapsing or progressive multiple sclerosis (MS). Participants take the drug twice daily for 2 years and undergo powerful 7T MRI scans to measure changes in brain volume, lesions, and tissue health. The goal is to see if the drug can slow MS progression and to check its safety and tolerability.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS (MS) PRIMARY PROGRESSIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain scans to reveal if new MS drug quietly calms inflammation
- Could a lighter MS treatment keep the disease at bay?
- A motorized hip brace may help MS patients walk better — small study puts it to the test
- Ear stimulation may help repair nerve damage in multiple sclerosis
- Could a gentle zapping of the brain ease MS fatigue and brain fog?
- Gentle exercise with cuffs may boost muscle in MS patients